Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Seminars in Immunopathology · 2024-08 · 46 (3-4)
DOI: 10.1007/s00281-024-01013-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Immunopathology, online erschienen am 16.07.2024. Verfasst von Andrew D Hughes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadel…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Cytokine Release Syndrome, Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
The advent of chimeric antigen receptor T cells (CAR-T) has been a paradigm shift in cancer immunotherapeutics, with remarkable outcomes reported for a growing catalog of malignancies. While CAR-T are highly effective in multiple diseases, salvaging patients who were considered incurable, they have unique toxicities which can be life-threatening. Understanding the biology and risk factors for these toxicities has led to targeted treatment approaches which can mitigate them successfully. The three toxicities of particular interest are cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and immune effector cell-associated hemophagocytic lymphohistiocytosis (HLH)-like syndrome (IEC-HS). Each of these is characterized by cytokine storm and hyperinflammation; however, they differ mechanistically with regard to the cytokines and immune cells that drive the pathophysiology. We summarize the current state of the field of CAR-T-associated toxicities, focusing on underlying biology and how this informs toxicity management and prevention. We also highlight several emerging agents showing promise in preclinical models and the clinic. Many of these established and emerging agents do not appear to impact the anti-tumor function of CAR-T, opening the door to additional and wider CAR-T applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
- Immune Dysregulation Frontier Program, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
- Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. diorioc@chop.edu.
- Immune Dysregulation Frontier Program, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. diorioc@chop.edu.
ORCID-Profile: Andrew D Hughes, David T Teachey, Caroline Diorio
Förderung
- NCI NIH HHS
- NICHD NIH HHS
Zitieren
APA
Hughes, A. D., Teachey, D. T., & Diorio, C. (2024). Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Seminars in Immunopathology, 46(3-4). https://doi.org/10.1007/s00281-024-01013-w
Vancouver
Hughes AD, Teachey DT, Diorio C. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Seminars in Immunopathology. 2024;46(3-4). doi:10.1007/s00281-024-01013-w
BibTeX
@article{Hughes2024,
author = {Hughes, Andrew D and Teachey, David T and Diorio, Caroline},
title = {Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy},
journal = {Seminars in Immunopathology},
year = {2024},
volume = {46},
number = {3-4},
doi = {10.1007/s00281-024-01013-w}
}
EUVIMED